Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

GENIXUS

Explore full profile

Critical thinking for critical care

Kannapolis, United StatesFounded 2020Health Tech & Medtech
Valuation $100–250M Last recorded · 2022
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for GENIXUS and the history behind them.

About GENIXUS

Genixus operates in the healthcare sector, specializing in the manufacturing and supply of acute and critical care medicines. The company serves healthcare providers, including hospitals and clinics, by offering high-quality, transparent, and reliable pharmaceutical products. Genixus sets itself apart by adhering to stringent quality standards and ensuring total transparency throughout its supply chain. All components and ingredients are sourced from FDA and EMA licensed partners in the United States and Europe. The company employs state-of-the-art manufacturing processes, similar to those used in advanced biologic and vaccine production, to ensure the highest level of sterility and safety. Genixus generates revenue through the sale of its pharmaceutical products to healthcare institutions, focusing on improving patient care and safety. The market it operates in is highly regulated, requiring compliance with various healthcare standards and regulations. The business model revolves around delivering innovative solutions that allow healthcare providers to focus on patient care, thereby safeguarding and improving lives.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
Kannapolis, United States
Employees
6
Open positions
None listed
Dealroom signal
56.2/100
Industry
Health
Sub-industry
Medical Devices
Sector
Health Tech & Medtech, Critical medical care, Pharmaceutical, Tech for Biotech and Pharma, Hard Tech, biomanufacturing
Business model
Manufacturing
Client focus
b2b

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Jan 2022 $20M $80M Undisclosed —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

GENIXUS website traffic

Latest recorded traffic for GENIXUS is 140 monthly website visits, down 22.2% over the last three months. GENIXUS's team grew 0% over the past year.

Latest monthly visits140 3-month web change-22.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about GENIXUS on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See GENIXUS’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.